
    
      ABSORB UK registry is a prospective, single arm, post-market registry designed to:

        -  Provide ongoing post-market surveillance for documentation of safety and clinical
           outcomes of the Absorb Everolimus Eluting BVS System in daily percutaneous coronary
           intervention (PCI) practice per Instructions for Use (IFU, on-label use).

        -  Collect additional information (e.g. acute success) to evaluate handling and
           implantation of Absorb BVS by physicians under a wide range of commercial use conditions
           and following routine clinical practice.
    
  